Vancouver’s Derm-Biome Pharmaceuticals has announced a collaboration with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.
Derm-Biome is a preclinical biopharmaceutical company dedicated to improving skin health. They have topical lead compounds for inflammatory skin diseases (acne and atopic dermatitis) and precancerous skin conditions/non-melanoma skin cancers that are both highly effective and well tolerated by skin.
Current standard of care chemotherapy-based creams damage normal skin, resulting in debilitating side effects that lead to poor patient compliance.
Derm-Biome has developed a second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.
Soaring skin cancer rates are reaching all-time highs in many parts of the world, and there are now more global deaths from non-melanoma skin cancers than melanoma itself.
“Chemotherapy creams have been topical treatment mainstays for precancerous skin conditions for over 60 years. These creams work, but they typically have considerable side effects. We see a significant opportunity in bringing a safe and highly effective topical skin cancer medication to the market,” commented Derm-Biome CEO Gordon Eberwein.
The Actinic Keratosis Treatment Market is expected to reach USD $9.7 billion by 2032 due in part to growing incidences of skin cancer and an increased demand for minimally invasive surgeries.
Leave a Reply